SynDaver is wait listing accredited individuals for our next private offering.

SynDaver is a mission-driven company from top to bottom. Our customers come first, our employees second and our investors third. Some people might find it odd that we would point this out on an investor page. However, because of this approach our products are by far the most innovative in the industry, our employees love working here and our sales are growing at a phenomenal rate. THIS is how you build shareholder value and sustainable growth at the same time.


SynDaver is famous for designing and building synthetic humans. These are made from water, salts and fibers and include all muscles, bones, organs, veins, arteries and other structures found in normal anatomy. The patented library of materials from which they are made mimic living tissues and are used across a wide range of industries, from medical device testing and surgical training, to secondary and college education, as well as consumer product development and crash testing.

Customer Base

Our customer base is broad, diverse, and global. We sell to every Fortune 500 medical device manufacturer, the best hospitals and medical schools in the world and educational institutions with EMT, nursing, anatomy, veterinary medicine, dentistry, engineering, mortuary science, surgical technician, physical therapy and sports science programs. We even sell to middle-school and high-school STEM education and biology programs.

Our industrial customers include the global technology elite: firms such as Apple, Facebook, Ford, General Electric, Google, Lear, Microsoft, Nike, Procter and Gamble, Underwriters Laboratories (UL) and many others.

Our government customers include the U.S. Food and Drug Administration, the U.S. Consumer Product Safety Commission, the U.S. State Department, the Health Services of Canada and the UK and every branch of the U.S. military. We also sell to NATO and friendly governments worldwide.

Our television customers include ABC, AMC, CBS, NBC, PBS and The Discovery Channel. Our products have been seen on too many news programs to list, as well as “Shark Tank” (ABC and CNBC), “Grey’s Anatomy” (ABC), “CSI” (CBS), “Inside Edition” (ABC), “Mythbusters” (Discovery), “Mythbusters 2.0” (Science Channel), “Crossbones” (NBC), “Shipping Wars” (AMC) and “Quest” (PBS).

Research and Development

SynDaver is constantly refining technologies, seeking new markets for existing products and designing new products for emerging applications. In 2017, we launched the SynDaver Surgical Canine for the veterinary medical education community, in 2018 we launched the SynDaver Advanced Modular Mannequin (SAMM), in 2019 we launched CopyCat and SynFrog for high school dissection and in 2020 we launched an entirely new line of 3D printers! In 2021 our activity will begin to accelerate with the launch of multiple products for science education, surgical training and medical device testing.

Historical Performance

SynDaver has been in business for nearly 20 years and over the most recent three-year period our average annual growth has exceeded 40%. To continue building on our success we are expanding our sales teams across multiple divisions, adding distributors worldwide, increasing marketing efforts and tapping new verticals with new products.

Corporate Governance

Dr. Christopher Sakezles is our Founder, Lead Engineer, Chief Technology Officer, CEO and Chairman of the Board of Directors for SynDaver. He is expected to remain in all of these positions indefinitely and controls a supermajority of company shares.

Investor Kit

SynDaver is not currently offering shares but we do so periodically via private offering. On such occasions we verify identity and require a nondisclosure agreement before a prospectus is released. Also please note that we do not currently distribute standard financial performance data to investors even under protection of NDA.

To be considered for future opportunities please fill out the form below. Our investment minimum is $100,000 USD.

    Check ALL That Apply:*

    Primary Interests:*

    synjoshFor Investors